Cancer causes & control : CCC · 2026
Trends in hepatitis B virus seroprevalence in a large cohort of adult cancer patients from 2010 to 2023.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rossi de Camargo Pinto Marina, de Paula Victória Gonçalves, Battaglia Débora Bignotto Rosane, de Oliveira Rafael, Ferreira Gustavo Manoel, Manchiero Caroline, Dantas Bianca Peixoto, Tengan Fátima Mitiko, Abdala Edson, Magri Mariana Cavalheiro
Аннотация
PURPOSE: Hepatitis B virus (HBV) infection poses increased risks for cancer patients due to immunosuppression and potential viral reactivation. We evaluated the seroprevalence and temporal trends of HBV exposure in a large cohort of cancer patients in Brazil.
METHODS: Adult patients who underwent anti-HBc testing at a quaternary oncology center between 2010 and 2023 were included in this retrospective study, and HBV exposure was defined as anti-HBc positivity. Temporal trends were assessed by using linear regression, whereas associated factors were evaluated by using multivariable logistic regression.
RESULTS: Anti-HBc testing was performed in 22.9% (28,869/125,985) of admitted cancer patients, and seroprevalence was 13.4% (3,857/28,869), declining from 16.5 in 2010 to 9.9% in 2023 (p < 0.001). Decreasing trends were observed across sexes and age groups (p < 0.001 for both), with a more pronounced decline among men (25.1%-12.3%). Seroprevalence also decreased significantly among White patients (16.7%-7.9%; p < 0.001) and those with solid tumors (18.8%-9.0%; p < 0.001), but not among non-White individuals (21.4%-17.7%; p = 0.246) or those with hematological malignancies (13.1%-12.8%; p = 0.136). Age ≥ 60 years (OR = 4.40; 95%CI: 3.77-5.12; p < 0.001), men (OR = 1.89; 95%CI: 1.76-2.04; p < 0.001), and non-White ethnicity/color (OR = 1.25; 95%CI: 1.15-1.35; p < 0.001) were independently associated with HBV exposure.
CONCLUSION: Despite the declining seroprevalence over time, HBV exposure remains common among cancer patients, as persistent disparities across demographic groups underscore the need for expanded vaccination and systematic screening.
METHODS: Adult patients who underwent anti-HBc testing at a quaternary oncology center between 2010 and 2023 were included in this retrospective study, and HBV exposure was defined as anti-HBc positivity. Temporal trends were assessed by using linear regression, whereas associated factors were evaluated by using multivariable logistic regression.
RESULTS: Anti-HBc testing was performed in 22.9% (28,869/125,985) of admitted cancer patients, and seroprevalence was 13.4% (3,857/28,869), declining from 16.5 in 2010 to 9.9% in 2023 (p < 0.001). Decreasing trends were observed across sexes and age groups (p < 0.001 for both), with a more pronounced decline among men (25.1%-12.3%). Seroprevalence also decreased significantly among White patients (16.7%-7.9%; p < 0.001) and those with solid tumors (18.8%-9.0%; p < 0.001), but not among non-White individuals (21.4%-17.7%; p = 0.246) or those with hematological malignancies (13.1%-12.8%; p = 0.136). Age ≥ 60 years (OR = 4.40; 95%CI: 3.77-5.12; p < 0.001), men (OR = 1.89; 95%CI: 1.76-2.04; p < 0.001), and non-White ethnicity/color (OR = 1.25; 95%CI: 1.15-1.35; p < 0.001) were independently associated with HBV exposure.
CONCLUSION: Despite the declining seroprevalence over time, HBV exposure remains common among cancer patients, as persistent disparities across demographic groups underscore the need for expanded vaccination and systematic screening.